Superiority Trials in Invasive Aspergillosis: A Harsh Reality Check With the IA-DUET (HOVON502) Trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 39378343.
- Also identified by DOI 10.1093/cid/ciae501 and PMC identifier 11848251.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The IA-DUET study aimed to compare azole-echinocandin combination therapy with azole monotherapy for invasive aspergillosis. Recruitment was hindered by patient ineligibility, competing studies, and guidelines favoring combination therapy when azole resistance was unknown. The low IA-attributable mortality suggests future trials may benefit from cluster randomization or composite endpoints to enhance efficiency.
Medical subject headings
- Antifungal Agents
- Azoles
- Echinocandins
- Aspergillosis
- Invasive Pulmonary Aspergillosis
- Equivalence Trials as Topic